pradigastat + fenofibrate

**Pradigastat + fenofibrate** is an experimental oral combination therapy studied for the treatment of severe hypertriglyceridemia. Pradigastat (LCQ908) is a small molecule inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1), which reduces the synthesis of triglycerides, thereby lowering plasma triglyceride levels[5]. Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases the oxidation of fatty acids and enhances lipoprotein lipase activity, also reducing triglycerides and improving lipid profile[5]. The combination has been evaluated in Phase 2 clinical trials for efficacy and safety, particularly for additional triglyceride lowering versus monotherapy in patients with severe hypertriglyceridemia[1][3][4][5][6].

Other names

LCQ908 + fenofibratepradigastat + fenofibrate